FPRX insider filings

FIVE PRIME THERAPEUTICS, INC. — 34 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-04-19. Screen FPRX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for FPRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — FIVE PRIME THERAPEUTICS, INC.

FiledFormInsiderReported transactionsSource
2021-04-194Collins Helen Louise — EVP and Chief Medical OfficerGift (G): 8,085 @ $0 · Grant/award (A): 66,000 @ $0 · Disposition to issuer (D): 135,547 @ $38 · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 58,000 (derivative) · +3 moreEDGAR
2021-04-194Nicholson Garry A — DirectorDisposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-04-194Sarena Francis Willard — Chief Strategy OfficerGift (G): 2,385 @ $0 · Gift (G): 795 @ $0 · Gift (G): 795 @ $0 · Gift (G): 795 @ $0 · Gift (G): 1,440 @ $0 · Gift (G): 2,460 @ $0 · +16 moreEDGAR
2021-04-194Smith David V — Executive Vice President & CFOGrant/award (A): 66,000 @ $0 · Disposition to issuer (D): 138,947 @ $38 · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 90,000 (derivative) · Disposition to issuer (D): 90,000 (derivative)EDGAR
2021-04-194White David — See RemarksDisposition to issuer (D): 33,423 @ $38 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 25,000 (derivative)EDGAR
2021-04-194RINGO WILLIAM R — DirectorGift (G): 10,000 @ $0 · Disposition to issuer (D): 16,600 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · +8 moreEDGAR
2021-04-194BERGER FRANKLIN M — DirectorDisposition to issuer (D): 5,000 @ $38 · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-04-194Dhingra Kapil — DirectorDisposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-04-194Jensen Peder — DirectorDisposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-04-194SCHAFER CAROL — DirectorDisposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 1,250 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-04-194Lyons-Williams Lori — DirectorDisposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-04-194Civik Thomas — President and CEO, DirectorDisposition to issuer (D): 68,971 @ $38 · Disposition to issuer (D): 480,000 (derivative)EDGAR
2021-04-134Civik Thomas — President and CEO, DirectorTax withholding (F): 11,088 @ $37.94EDGAR
2021-03-024Sarena Francis Willard — Chief Strategy OfficerTax withholding (F): 1,158 @ $22.23EDGAR
2021-03-024Collins Helen Louise — EVP and Chief Medical OfficerTax withholding (F): 1,158 @ $22.23EDGAR
2021-03-024White David — See RemarksTax withholding (F): 1,461 @ $22.23EDGAR
2021-02-264Sarena Francis Willard — Chief Strategy OfficerTax withholding (F): 5,100 @ $25.71 · Tax withholding (F): 1,653 @ $23.08EDGAR
2021-02-264Collins Helen Louise — EVP and Chief Medical OfficerTax withholding (F): 5,091 @ $25.71 · Tax withholding (F): 1,653 @ $23.08EDGAR
2021-02-264Smith David V — Executive Vice President & CFOTax withholding (F): 5,110 @ $25.71EDGAR
2021-02-264White David — See RemarksTax withholding (F): 1,155 @ $25.71EDGAR
2020-12-154Sarena Francis Willard — Chief Strategy OfficerOption exercise (M): 22,000 @ $0 · Tax withholding (F): 11,583 @ $16.14 · Option exercise (M): 22,000 (derivative) @ $0EDGAR
2020-12-154Smith David V — Executive Vice President & CFOOption exercise (M): 22,000 @ $0 · Tax withholding (F): 11,504 @ $16.14 · Option exercise (M): 22,000 (derivative) @ $0EDGAR
2020-12-154Collins Helen Louise — EVP and Chief Medical OfficerOption exercise (M): 22,000 @ $0 · Tax withholding (F): 11,583 @ $16.14 · Option exercise (M): 22,000 (derivative) @ $0EDGAR
2020-11-304Smith David V — Executive Vice President & CFOTax withholding (F): 6,920 @ $18.45EDGAR
2020-11-134Sarena Francis Willard — Chief Strategy OfficerOption exercise (M): 22,000 @ $0 · Tax withholding (F): 11,001 @ $18 · Option exercise (M): 22,000 (derivative) @ $0EDGAR
2020-11-134Smith David V — Executive Vice President & CFOOption exercise (M): 22,000 @ $0 · Tax withholding (F): 10,908 @ $18 · Option exercise (M): 22,000 (derivative) @ $0EDGAR
2020-11-134Collins Helen Louise — EVP and Chief Medical OfficerOption exercise (M): 22,000 @ $0 · Tax withholding (F): 11,039 @ $18 · Option exercise (M): 22,000 (derivative) @ $0EDGAR
2020-11-134RINGO WILLIAM R — DirectorOption exercise (M): 52,959 @ $2.22 · Sale (S): 52,959 @ $22.50 · Option exercise (M): 26,000 @ $2.80 · Sale (S): 26,000 @ $22.50 · Option exercise (M): 52,959 (derivative) @ $0 · Option exercise (M): 26,000 (derivative) @ $0EDGAR
2020-11-134BVF PARTNERS L P/IL
BIOTECHNOLOGY VALUE FUND L P
BVF I GP LLC
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC
BVF INC/IL
LAMPERT MARK N
Sale (S): 3,941,214 @ $20.19 · Sale (S): 2,949,477 @ $20.19 · Sale (S): 502,649 @ $20.19EDGAR
2020-11-064BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P — 10% owner
BVF I GP LLC — 10% owner
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Purchase (P): 257,804 @ $4.88 · Purchase (P): 17,230 @ $4.98 · Purchase (P): 143,403 @ $4.88 · Purchase (P): 10,436 @ $4.98 · Purchase (P): 15,355 @ $4.88 · Purchase (P): 2,334 @ $4.98EDGAR
2020-10-084BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P — 10% owner
BVF I GP LLC — 10% owner
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Purchase (P): 157,782 @ $5.04 · Purchase (P): 162,352 @ $5.04 · Purchase (P): 25,107 @ $5.04EDGAR
2020-10-024White David — See RemarksTax withholding (F): 6,916 @ $4.70EDGAR
2020-09-244BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P — 10% owner
BVF I GP LLC — 10% owner
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Purchase (P): 32 @ $3.80EDGAR
2020-08-244Collins Helen Louise — EVP and Chief Medical OfficerTax withholding (F): 827 @ $4.69EDGAR

Recent 8-K events — FIVE PRIME THERAPEUTICS, INC.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2021-04-168-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2021-04-158-K8.01 — Other EventsEDGAR
2021-03-048-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2021-01-158-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2021-01-158-K2.02 — Results of Operations and Financial ConditionEDGAR
2020-11-178-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-138-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-108-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-038-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-028-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=FPRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs